doranidazole

Known as: (2RSs,3SR)-3-((2-nitroimidazol-1-yl)methoxy)butane-1,2,4-triol 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2000-2018
01220002018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Glioblastoma is one of the intractable cancers and is highly resistant to ionizing radiation. This radioresistance is partly due… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2008
2008
OBJECTIVE This study was designed to assess the potential of the nitroaromatic radiosensitizer doranidazole to preferentially… (More)
Is this relevant?
2008
2008
Novel hypoxic cell radiosensitiser doranidazole was tested for unresectable pancreatic cancer administered at intraoperative… (More)
  • figure 1
  • table 1
Is this relevant?
2007
2007
PURPOSE This Phase I/II trial was conducted to assess the efficacy and safety of PR-350, a novel hypoxic cell radiosensitizer… (More)
Is this relevant?
2005
2005
We have investigated the radiosensitizing effect of doranidazole, a hypoxic cells radiosensitizer, using SCCVII tumor cells of… (More)
Is this relevant?
2002
2002
This study was performed to confirm the radiation-chemical properties of the 2-nitroimidazole derivative doranidazole, (+/-)-(2RS… (More)
Is this relevant?
2002
2002
We investigated the sensitizing effect of the 2-nitroimidazole analogue doranidazole, a new hypoxic radiosensitizer, on radiation… (More)
Is this relevant?
2001
2001
A phase Ia study of a 2-nitroimidazole nucleoside analog radiosensitizer doranidazole was conducted to evaluate its toxicity and… (More)
Is this relevant?
2000
2000
BACKGROUND AND PURPOSE A clinical study of the new 2-nitroimidazole nucleoside analogue doranidazole (PR-350) in combination with… (More)
Is this relevant?
2000
2000
A new 2-nitroimidazole radiosensitizer doranidazole is now undergoing clinical evaluation in combination with intraoperative… (More)
Is this relevant?